Mavatrep information

Mavatrep
Clinical data
Other names	JNJ-39439335
Identifiers
	IUPAC name 2-[2-[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-3H-benzimidazol-5-yl]phenyl]propan-2-ol;
CAS Number	956274-94-5;
PubChem CID	17751090;
DrugBank	DB12875;
ChemSpider	29271895;
UNII	F197218T99;
ChEMBL	ChEMBL2364618;
CompTox Dashboard (EPA)	DTXSID90241905 ;
Chemical and physical data
Formula	C25H21F3N2O
Molar mass	422.451 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)/C=C/C4=CC=C(C=C4)C(F)(F)F)O;
	InChI InChI=1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+; Key:ORDHXXHTBUZRCN-NTEUORMPSA-N;

Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist.^[1] It is an investigational analgesic that may be a potential treatment for pain and/or inflammation.

Phase I trials have been completed in healthy Japanese and Caucasian volunteers.^[1]^[2]

Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.^[2]

^ ^a ^b Manitpisitkul P, Shalayda K, Russell L, Sanga P, Williams Y, Solanki B, et al. (September 2018). "Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies". Clinical Pharmacology in Drug Development. 7 (7): 699–711. doi:10.1002/cpdd.412. PMID 29125700. S2CID 32666782.
^ ^a ^b Manitpisitkul P, Shalayda K, Russell L, Sanga P, Solanki B, Caruso J, et al. (September 2018). "Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study". Clinical Pharmacology in Drug Development. 7 (7): 712–726. doi:10.1002/cpdd.413. PMID 29125703. S2CID 11755963.

[:0-1] Manitpisitkul P, Shalayda K, Russell L, Sanga P, Williams Y, Solanki B, et al. (September 2018). "Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies". Clinical Pharmacology in Drug Development. 7 (7): 699–711. doi:10.1002/cpdd.412. PMID 29125700. S2CID 32666782.

[:1-2] Manitpisitkul P, Shalayda K, Russell L, Sanga P, Solanki B, Caruso J, et al. (September 2018). "Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study". Clinical Pharmacology in Drug Development. 7 (7): 712–726. doi:10.1002/cpdd.413. PMID 29125703. S2CID 11755963.

Mavatrep information

and 29 Related for: Mavatrep information

Mavatrep

List of investigational analgesics

Onion

Tobacco

Turmeric

Thyme

Ruta graveolens

Rosemary

Mentha

Hypericum perforatum

Black pepper

Formaldehyde

Cannabis

Clotrimazole

Oregano

Clove

Wasabi

Camphor

Paracetamol

Hydrogen peroxide

Ginger

Horseradish

Capsaicin

Basil

Cannabidiol

Menthol

Sichuan pepper

Curcumin

Tetrahydrocannabinol